Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is younger than 18 years of age on day 1~* Patient weighs at least 44 pounds (20 kg)~* The patient's active tics are causing distress or impairment~* Patient is able to swallow study medication whole~* Patient is in good general health~* Women/girls of childbearing potential whose male partners are of childbearing potential must use contraception for the duration of the study -- Additional criteria apply, please contact the investigator for more information~Exclusion Criteria:~* Patient is 18 years of age or older.~* Patient has a neurologic disorder other than TS that could obscure the evaluation of tics.~* The patient's predominant movement disorder is stereotypy (coordinated movements that repeat continually and identically) associated with autism spectrum disorder.~* Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder.~* Patient has clinically significant depression at screening or day 1. Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose for at least 6 weeks before screening.~* Patient has a history of suicidal intent or related behaviors within 2 years of screening~* Patient has a history of a previous actual, interrupted, or aborted suicide attempt.~* Patient has a first-degree relative who has completed suicide.~* Patient has clinically significant obsessive-compulsive disorder (OCD) on day 1 that, in the opinion of the investigator, is the primary cause of impairment.~* Patient has received comprehensive behavioral intervention for tics for TS or cognitive behavioral therapy for OCD within 4 weeks of screening.~* Patient has received treatment with deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation for reduction of tics within 4 weeks of the screening visit.~* Patient has an unstable or serious medical illness at screening or day 1~* Patients with a history of torsade de pointes, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure.~* Patient has received a monoamine oxidase inhibitor within 14 days of the day 1 visit.~* Patient has participated in an investigational drug or device study (with the exception of Study SD-809-C-17, Study TV50717-CNS-30046, or Study TV50717-CNS-30060) and received IMP/intervention within 30 days or 5 drug half-lives of day 1, whichever is longer.~* The patient is a pregnant or lactating female, or plans to become pregnant during the study.~* Patient has a history of, or acknowledges, alcohol-related disorder in the previous 12 months -- Additional criteria apply, please contact the investigator for more information

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- TEV-50717- Part A (Type: EXPERIMENTAL): All patients will undergo TEV-50717 dose titration in this study. Patients will receive 6 mg of TEV-50717 with food on the evening of day 1. The titration scheme and maximum dose will be determined by body weight and cytochrome P450 2D6 (CYP2D6) impairment status from the parent study.
- TEV-50717- Part B RW (Type: EXPERIMENTAL): TEV-50717 is administered during Part B Randomized Drug Withdrawal (RW) 2-week period.
- Placebo- Part B RW (Type: PLACEBO_COMPARATOR): Placebo is administered during Part B Randomized Drug Withdrawal (RW) 2-week period only.

Based on this trial design, predict the completion outcome and termination type (if applicable).